Anti-TNF Therapy Induces CD4+ T-Cell Production of IL-22 and Promotes Epithelial Repairs in Patients with Crohn's Disease

Leilei Fang, Zhi Pang, Weigang Shu, Wei Wu, Mingming Sun, Yingzi Cong, Zhanju Liu

    Research output: Contribution to journalArticle

    11 Scopus citations

    Abstract

    Background Anti-tumor necrosis factor (TNF) therapy appears to be effective in the treatment of Crohn's disease (CD), a chronic inflammatory disease of the gastrointestinal tract. However, the mechanisms involved are not completely understood. Methods Fifty-seven active CD patients were enrolled, and cytokine profiles in colonic biopsies of patients with active CD receiving anti-TNF monoclonal antibody (mAb) (infliximab [IFX]) treatment were determined using quantitative real-time polymerase chain reaction (qRT-PCR). Colonic biopsies of active CD patients and healthy donors were cultured with IFX in vitro, and cytokine profiles were measured by qRT-PCR. Peripheral blood (PB)-CD4+ T cells were stimulated with anti-CD3 and anti-CD28 mAbs in the presence of human immunoglobin (HIg), IFX, recombinant human TNF-α converting enzyme (rhTACE), and aryl hydrocarbon receptor (AhR) inhibitor (CH-223191), respectively, to determine interleukin (IL)-22 expression by CD4+ T cells. Caco2 cells were also utilized to study their potential role in modulating epithelial cell barrier repairs in vitro. Results IFX therapy markedly upregulated IL-22 mRNA expression in the gut mucosa of CD patients. In vitro treatment with IFX greatly promoted CD CD4+ T cells to express IL-22, which was inhibited by rhTACE, indicating that reverse signaling through binding to membrane-bound TNF mediates anti-TNF-induced IL-22 expression of CD CD4+ T cells. However, blockade of AhR markedly inhibited anti-TNF-induced IL-22+CD4+ T (Th22) cell differentiation in CD patients. Moreover, treatment with IL-22 induced intestinal epithelial cell expression of tight junction proteins (eg, claudin1 and ZO-1) and facilitated transepithelial resistance, indicating that IL-22 protects intestinal mucosa from inflammation via maintenance of epithelial barrier integrity. Conclusions Our results uncover a novel mechanism whereby anti-TNF therapy upregulates IL-22 production in CD patients through promoting Th22 cell differentiation and contributes to intestinal epithelial barrier repairs.

    Original languageEnglish (US)
    Pages (from-to)1733-1744
    Number of pages12
    JournalInflammatory Bowel Diseases
    Volume24
    Issue number9
    DOIs
    StatePublished - Aug 16 2018

    Keywords

    • anti-TNF mAb
    • Crohn's disease
    • epithelial barrier function
    • IL-22
    • Th22 cells

    ASJC Scopus subject areas

    • Immunology and Allergy
    • Gastroenterology

    Fingerprint Dive into the research topics of 'Anti-TNF Therapy Induces CD4<sup>+</sup> T-Cell Production of IL-22 and Promotes Epithelial Repairs in Patients with Crohn's Disease'. Together they form a unique fingerprint.

  • Cite this